Alnylam Pharmaceuticals' (ALNY) Subcutaneous Amvuttra ATTR-PN Approval Is a Key Step for Growth Expansion Plan - Jefferies
Tweet Send to a Friend
Jefferies analyst Maury Raycroft reiterated a Buy rating and $218.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) after the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
